Articles related to TYPE 2 DIABETES

Let’s delve into the groundbreaking application of endoscopic electroporation and semaglutide that’s changing the game in diabetes management. First off, the EMINENT study is unveiling a revolutionary approach in treating type 2 diabetes. This method combines endoscopic electroporation, known as ReCET, with the medication semaglutide. The main goal is to reduce or potentially eliminate the need for insulin, revolutionizing glycemic control. The innovative ReCET procedure employs electroporation to ablate the superficial layer of mucosa in the small intestine. Researchers hope that by rejuvenating the duodenal lining and employing a GLP-1 receptor agonist, they could address insulin resistance, the fundamental problem in type 2 diabetes. Interestingly, ReCET doesn’t use extreme temperatures to ablate intestinal tissue. Rather, it uses a pulsed electric field, yielding precise control and limited depth of penetration. This method disrupts the cellular membrane of the mucosa and superficial submucosa, triggering natural cell death within a day, thereby significantly minimizing the risk of complications. A single-arm pilot study conducted as part of EMINENT involved 14 patients with type 2 diabetes using long-acting basal insulin. All patients underwent the ReCET procedure and started on semaglutide two weeks later. Researchers noted the feasibility and safety of ReCET, with a 100% success […]

A retrospective cohort study was conducted to investigate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) for individuals without preexisting cardiovascular disease. The study included US veterans aged 18 or older who were receiving care from the Veterans Health Administration. The cohort consisted of patients who added either GLP1RA, SGLT2i, or dipeptidyl peptidase-4 inhibitors (DPP4i) to their existing diabetes treatments. The outcomes measured were MACE and heart failure hospitalization. The results showed that the addition of GLP1RA was associated with a lower incidence of MACE and heart failure compared to DPP4i. However, the addition of SGLT2i did not show a significant association with primary prevention of MACE.

According to census data, there are 49.2 million older persons in the United States, with 21 million (42.6%) earning less than 200% of the federal poverty threshold. With the majority of older persons having their natural dentition, there will be an increased demand for oral health (OH) treatments among this demographic. Although the causative links between oral and systemic diseases are still developing and not entirely established, there is undeniably a bidirectional relationship between OH, cardiovascular disease, and diabetes in older persons.

Given at a higher dose than for DM2, a weekly semaglutide injection sustainably reduced weight by an average of 15% together with diet. What are the precautions? And what else is on the horizon in the class?

In this study published in the Journal of Restorative Dentistry, in both the diabetic and non-diabetic groups, there was no statistically significant difference in the overall pain felt by patients after a single visit and after two visits. Further research on a larger sample size is necessary to definitively determine if diabetes can serve as a disease modifier and alter postoperative pain in irreversible pulpitis following a single-visit RCT in managed T2 diabetics.

Per the Standards, “diabetes management in older adults requires regular assessment of medical, psychological, functional, and social domains. Older adults with diabetes have higher rates of premature death, functional disability, accelerated muscle loss, and coexisting illnesses … and … are also at greater risk for several common geriatric syndromes, such as polypharmacy, cognitive impairment, depression, urinary incontinence, injurious falls, persistent pain, and frailty. All these can impair their self-management.”